+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Glaucoma Market Insight, Epidemiology and Market Forecast - 2032

  • PDF Icon

    Report

  • 338 Pages
  • June 2023
  • Region: Global
  • DelveInsight
  • ID: 5322345

Key Highlights:

  • Total diagnosed prevalent cases of Glaucoma were estimated at nearly 7.3 million in 2022 in the 7MM, however overall burden of Glaucoma has been estimated to be nearly 17 million (Prevalent cases) in 2022 in the 7MM.
  • Most diagnosed Glaucoma patients were estimated in the US, followed by Japan, Germany, and France in 2022.
  • Open Angle Glaucoma is most prominent type of Glaucoma with high burden in the 7MM.
  • As per the publisher's estimations, the US consistently captured the highest market size with USD 2.6 billion net sales revenue among the 7MM, whereas the UK had the lowest market with a market size of nearly USD 140 million.
  • The current treatment market for Glaucoma includes Prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors, fixed Combinations, alpha-2-selective adrenergic agonists, and Others.
  • The total market size of the Glaucoma is anticipated to upsurge during the forecast period due to the expected entry of emerging therapies that includes iDose TR (travoprost intraocular implant), NCX 470, OTX-TIC, and others.
This “Glaucoma - Market Insights, Epidemiology and Market Forecast - 2032” report delivers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology and the Glaucoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Glaucoma market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM, Glaucoma market size from 2019 to 2032. The report also covers current Glaucoma treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain) and the United Kingdom
  • Japan
Study Period: 2019-2032

Disease Understanding and Treatment Algorithm

Glaucoma Overview

According to the American Academy of Ophthalmology, glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma (OAG) and narrow-angle glaucoma/angle-closure glaucoma (ACG). Glaucoma often does not cause noticeable symptoms in the early stages, so it is often called the “silent thief of sight.” As the condition progresses, peripheral (side) vision may be affected, gradually narrowing the visual field.

Glaucoma Diagnosis

Although glaucoma is not curable, early diagnosis and adequate treatment effectively reduce or prevent further optic nerve (ON) damage. The diagnosis of glaucoma typically involves a comprehensive eye examination and several specific tests, namely, tonometry (measurement of intraocular pressure), an ophthalmoscopy (evaluation of the optic nerve for signs of damage), visual field testing (perimetry), gonioscopy (assessing the drainage angle of the eye to determine the type of glaucoma) to assess the health of the optic nerve and evaluate IOP levels.

The diagnosis of glaucoma typically involves a combination of clinical evaluation, visual field testing, optic nerve examination, and measurement of intraocular pressure (IOP). The diagnosis guidelines for glaucoma can vary to some extent based on geographical regions and medical societies, such as separate guidelines published by American Academy of Ophthalmology, European Glaucoma Society Terminology, and others.

Further details related to country-based variations are provided in the report

Glaucoma Treatment

There is no cure for glaucoma, but early treatment can often stop the damage and protect the vision. Doctors use a few different types of treatment for glaucoma, including medicines (usually eye drops), laser treatment, and surgery.

Glaucoma is treated by lowering the eye pressure (intraocular pressure), and depending on the situation, management includes prescription eye drops, oral medications, laser treatment, surgery, or a combination of any of these.

Medicines: Medications for glaucoma treatment aim to lower IOP by decreasing AH production and increasing AH outflow. Prostaglandin analogs and beta-blockers are currently the most frequently used agents.

Surgery: The most common type of surgery for glaucoma is called trabeculectomy. It involves removing part of the eye-drainage tubes to allow fluid to drain more easily.

Glaucoma Epidemiology

As the market is derived using the patient-based model, the Glaucoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Glaucoma, Total Diagnosed Prevalent Cases of Glaucoma, Type-specific Diagnosed Prevalent Cases Glaucoma, Type-specific Diagnosed Prevalent Cases Open-angle Glaucoma, Gender-specific Diagnosed Prevalent Cases Glaucoma, and Age-specific Diagnosed Prevalent Cases of Glaucoma in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032. The total prevalent cases of Glaucoma in the 7MM comprised approximately 17 million cases in 2022 and are projected to increase during the forecast period.
  • Glaucoma remain undetected in most of the patients due to many factors. According to the publisher estimations, of 17 million prevalent cases in 2022 in the 7MM, only 7 million are estimated to have received a formal diagnosis.
  • The US showed the highest diagnosed prevalent population of Glaucoma compared to other 7MM countries, with nearly 2.6 million cases in 2022. As per the publisher's estimates, the country alone accounts for nearly 35% of total diagnosed prevalent cases, for Glaucoma in the 7MM, followed by Japan, contributing 22% of all the Glaucoma cases.
  • Glaucoma can affect both men and women, however the ratio of male to female Glaucoma patients suggest that female are predominantly affected more than males. In 2022, there were 3,362,578 cases of glaucoma among male population and 3,960,115 cases among female population.
  • The diagnosed prevalent cases of glaucoma were further divided into open-angle glaucoma (OAG) and closed-angle glaucoma. The distribution showed that nearly 90% of glaucoma cases are of OAG type.
  • Primary Open-Angle Glaucoma (POAG) and Secondary Open-Angle Glaucoma (SOAG) are two types of Open-angle glaucoma. This estimates showed that POAG and SOAG comprised 90% and 10% cases of OAG, respectively.
  • Normal tension glaucoma (NTG) is a subtype of POAG occurring in the presence of normal IOP. As per the publisher's estimates, of all POAG cases in the 7MM, 52% were of NTG type.
  • Among EU4 and the UK, Germany had the highest diagnosed prevalent population of glaucoma, with 0.7 million cases, followed by France in 2022. On the other hand, Spain had the lowest diagnosed prevalent population of glaucoma among EU4 and the UK in 2022.
  • Japan accounted for 22% of the total diagnosed prevalent cases of Glaucoma in the 7MM in 2022.

Glaucoma Drug Chapters

The drug chapter segment of the Glaucoma report encloses a detailed analysis of Glaucoma marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands the Glaucoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Marketed Drugs

ROCKLATAN/ ROCLANDA (netarsudil/latanoprost, 0.02%/0.005%): Aerie Pharmaceuticals

Roclanda (in Europe), known as Rocklatan in the United States, is fixed-dose combination of a Rho kinase inhibitor and a prostaglandin F2a analog that reduces elevated intraocular pressure (IOP) in individuals diagnosed with open-angle glaucoma or hypertension. While it obtained approval in the US in March 2019, it recently gained approval in the European region in January 2021.

DURYSTA (bimatoprost SR): AbbVie Inc.

DURYSTA is an ophthalmic drug delivery system for a single intracameral administration of a biodegradable bimatoprost implant which is believed to lower IOP in humans by increasing the outflow of aqueous humor through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional). It imitates the effects of prostamides, specifically prostaglandin F2a.

Note: Detailed marketed therapies assessment will be provided in the final report of Glaucoma.

Emerging Drugs

NCX-470: Nicox Ophthalmics

NCX 470 is an investigational ophthalmic treatment by Nicox Ophthalmics designed to address ocular hypertension and open-angle glaucoma. It belongs to the second-generation nitric oxide (NO) category-donating prostaglandin analogs. This therapeutic candidate is administered through the ophthalmic route, targeting the prostaglandin F2 alpha receptor and soluble guanylate cyclase to achieve its effects.

Based on a dual mechanism of action, NCX 470, a monotherapy, has the potential to be a new standard of care in reducing IOP glaucoma patients.

iDose TR (Travoprost Intraocular Implant): Glaukos Corporation

Glaukos Corporation is developing the iDose TR, which incorporates an innovative formulation of travoprost, a prostaglandin analog for reducing intraocular pressure (IOP). This treatment is surgically placed within the eye through a micro-invasive procedure, enabling the continuous release of therapeutic amounts of travoprost for a minimum of 1 year.

iDose TR has been granted with the Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA's review set for December 22, 2023. If approved, this will be a game changer bridging the existing incumbent drug delivery format associated with the current treatment pattern.

Note: Detailed emerging therapies assessment will be provided in the final report of Glaucoma.

Drug Class Insights

Management of the disease focuses on lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, rho kinase inhibitors (ROCK) and carbonic anhydrase inhibitors. Prostaglandin analogs increase fluid outflow, beta-blockers reduce fluid production, alpha-adrenergic agonists decrease fluid production and increase outflow, carbonic anhydrase inhibitors reduce fluid production, rho kinase inhibitors increase fluid outflow, and cholinergic agonists increase fluid drainage.

The choice of medication depends on factors such as glaucoma severity, patient response, and potential side effects.

Glaucoma Market Outlook

The primary objective of disease management is to reduce intraocular pressure (IOP), typically accomplished through the use of various drug classes such as prostaglandin analogs, beta-blockers, alpha-agonists, rho kinase inhibitors (ROCK), and carbonic anhydrase inhibitors. However, not all patients benefit from these treatments, as some may still experience optic nerve deterioration despite having normal IOP levels. In addition to pharmacological interventions, alternative measures such as incisional surgery, laser surgery, and medication are also commonly recommended.

The launch of emerging therapies, such as NCX 470 (Nicox Ophthalmics), PDP-716 (Sun Pharma Advanced Research Company Limited (SPARC)/ Visiox Pharma), TC-002 (TearClear), and others are expected to impact the market positively.
  • The total market size of Glaucoma in the 7MM was around USD 4.2 billion in 2022. This is estimated to increase by 2032 at a significant CAGR.
  • In the 7MM, most of the market share was accommodated by prostaglandin analogs generating nearly USD 2.6 billion, followed by fixed combination therapies in 2022.
  • Among the 7MM, the US captured the highest market in 2022, covering a total of 63% market, followed by Japan which is anticipated to grow during the forecast period (2023-2032).
  • In 2022, EU4 and the UK captured nearly 24% of the total market in the 7MM.
  • Among the forecasted emerging therapies, iDose TR is expected to capture the highest market in the 7MM by 2032.

Glaucoma Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2019-2032. For example, for PDP-716, in the US we expect the drug uptake to be Slow-medium with a probability-adjusted peak share of around 2%, and years to the peak is expected to be 8 years from the year of launch.

Glaucoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Glaucoma emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Glaucoma evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Duke University Eye Center; Glaucoma Research Foundation; Centre Hospitalier National d'Ophtalmologie; European Board of Ophthalmology; Department of Ophthalmology, Kyushu University; and others.

This analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Glaucoma market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

The publisher performs Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment of glaucoma is a major factor restraining the growth of the global glaucoma drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment. In the US, between 2000 and 2020, the average adjusted reimbursement for the 22 analyzed procedures decreased by 20.5%. Reimbursement is a crucial factor that affects the drug's access to the market. Market access and reimbursement options can differ depending on regulatory status, target population size, care setting, unmet need, the magnitude of incremental benefit claims, and costs.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

  • The report covers a segment of key events, an executive summary, descriptive overview of Glaucoma, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
  • Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
  • Additionally, an all-inclusive account of the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will impact the current treatment landscape.
  • A detailed review of the Glaucoma market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preference that help shape and drive the 7MM Glaucoma market.

Glaucoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Glaucoma Pipeline Analysis
  • Glaucoma Market Size and Trends
  • Existing and Future Market Opportunity

Glaucoma Report Key Strengths

  • Ten Years Forecast
  • The 7MM Coverage
  • Glaucoma Epidemiology Segmentation
  • Key Cross Competition
  • Attribute Analysis
  • Drugs Uptake and Key Market Forecast Assumptions

Glaucoma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions Answered

Market Insights

  • What was the Glaucoma total market size, the market size by therapies, and market share (%) distribution in 2019, and how would it all look in 2032? What are the contributing factors for this growth?
  • What unmet needs are associated with the current treatment market of Glaucoma?
  • What will be the impact of the XELPROS patent expiry in the market?
  • How will OMLONTI compete with the existing therapies for Glaucoma during the study period?
  • Which drug is going to be the largest contributor in 2032?
  • What are the pricing variations among different geographies for approved and off-label therapies?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

  • What are the disease risk, burdens, and unmet needs of Glaucoma? What will be the growth opportunities across the 7MM concerning the patient population of Glaucoma?
  • What is the historical and forecasted Glaucoma patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
  • Why do only limited patients appear for diagnosis?
  • Which type of Glaucoma is more prevalent and why?
  • What factors are affecting the diagnosis of the indication?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

  • What are the current options for treating Glaucoma? What are the current guidelines for treating Glaucoma in the US and Europe?
  • How many companies are developing therapies for treating Glaucoma?
  • How many emerging therapies are in the mid-stage and late stage of development for treating Glaucoma?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the key designations that have been granted for the emerging therapies for Glaucoma?
  • What is the cost burden of approved therapies on the patient?
  • Patient acceptability in terms of preferred treatment options as per real-world scenarios?
  • What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
  • What are the 7MM historical and forecasted markets of Glaucoma?

Reasons to Buy

  • The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Glaucoma Market.
  • Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
  • Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
  • Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
  • To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
  • Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights2. Report Introduction
3. Country-wise Glaucoma Market Overview at a Glance
3.1. Country-wise Market Share (%) Distribution of Glaucoma in 2019
3.2. Country-wise Market Share (%) Distribution of Glaucoma in 2032
4. Glaucoma Market Overview by Class
4.1. Market Share (%) Distribution of Glaucoma by Class in 2019
4.2. Market Share (%) Distribution of Glaucoma by Class in 2032
5. Methodology of Glaucoma Epidemiology and Market6. Executive Summary of Glaucoma7. Key Events
8. Disease Background and Overview of Glaucoma
8.1. Introduction
8.2. Classification of Glaucoma
8.3. Signs and Symptoms of Glaucoma
8.4. Genes Involved in Glaucoma
8.5. Diagnosis
8.5.1. Diagnostic Algorithm
8.5.2. Diagnostic Guidelines
8.5.2.1. Primary Glaucoma Preferred Practice Pattern Guidelines
8.5.2.2. European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition
8.5.2.3. National Institute for Health and Care Excellence (NICE) Guidelines for Glaucoma diagnosis
8.6. Treatment and Management of Glaucoma
8.6.1. Treatment Algorithm
8.6.2. Treatment and Management Guidelines
8.6.2.1. International Council of Ophthalmology Guidelines for Glaucoma Eye Care
8.6.2.2. Level of Evidence and Recommendation in Medical Treatment of PACG
8.6.2.3. European Glaucoma Society Terminology and Guidelines for Glaucoma
8.6.2.4. Primary Open-angle Glaucoma Preferred Practice Pattern guidelines
8.6.2.5. National Institute for Health and Care Excellence (NICE) Guidelines for Glaucoma Management
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale: The 7MM
9.2.1. Diagnosed Prevalent Cases of Glaucoma
9.2.2. Type-specific Diagnosed Prevalent Cases
9.2.3. Gender-specific Diagnosed Prevalent Cases of Glaucoma
9.2.4. Age-specific Diagnosed Prevalent Cases of Glaucoma
9.3. Total Prevalent Cases of Glaucoma in the 7MM
9.4. Total Diagnosed Prevalent Cases of Glaucoma in the 7MM
9.5. The United States
9.5.1. Total prevalent cases of Glaucoma in the US
9.5.2. Total diagnosed prevalent cases of Glaucoma in the US
9.5.3. Type-specific Diagnosed Prevalent Cases of Glaucoma in the US
9.5.4. Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in the US
9.5.5. Gender-specific Diagnosed Prevalent Cases of Glaucoma in the US
9.5.6. Age-specific Diagnosed Prevalent Cases of Glaucoma in the US
9.6. Major Five European Countries
9.6.1. Germany
9.6.1.1. Total Prevalent Cases of Glaucoma
9.6.1.2. Total Diagnosed Prevalent Cases of Glaucoma
9.6.1.3. Type-specific Diagnosed Prevalent Cases of Glaucoma
9.6.1.4. Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma
9.6.1.5. Gender-specific Diagnosed Prevalent Cases of Glaucoma
9.6.1.6. Age-specific Diagnosed Prevalent Cases of Glaucoma
9.6.2. France
9.6.2.1. Total Prevalent Cases of Glaucoma
9.6.2.2. Total Diagnosed Prevalent Cases of Glaucoma
9.6.2.3. Type-specific Diagnosed Prevalent Cases of Glaucoma
9.6.2.4. Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma
9.6.2.5. Gender-specific Diagnosed Prevalent Cases of Glaucoma
9.6.2.6. Age-specific Diagnosed Prevalent Cases of Glaucoma
9.6.3. Italy
9.6.3.1. Total Prevalent Cases of Glaucoma
9.6.3.2. Total Diagnosed Prevalent Cases of Glaucoma
9.6.3.3. Type-specific Diagnosed Prevalent Cases of Glaucoma
9.6.3.4. Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma
9.6.3.5. Gender-specific Diagnosed Prevalent Cases of Glaucoma
9.6.3.6. Age-specific Diagnosed Prevalent Cases of Glaucoma
9.6.4. Spain
9.6.4.1. Total Prevalent Cases of Glaucoma
9.6.4.2. Total Diagnosed Prevalent Cases of Glaucoma
9.6.4.3. Type-specific Diagnosed Prevalent Cases of Glaucoma
9.6.4.4. Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma
9.6.4.5. Gender-specific Diagnosed Prevalent Cases of Glaucoma
9.6.4.6. Age-specific Diagnosed Prevalent Cases of Glaucoma
9.6.5. The UK
9.6.5.1. Total Prevalent Cases of Glaucoma
9.6.5.2. Total Diagnosed Prevalent Cases of Glaucoma
9.6.5.3. Type-specific Diagnosed Prevalent Cases of Glaucoma
9.6.5.4. Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma
9.6.5.5. Gender-specific Diagnosed Prevalent Cases of Glaucoma
9.6.5.6. Age-specific Diagnosed Prevalent Cases of Glaucoma
9.7. Japan
9.7.1. Total prevalent cases of Glaucoma in Japan
9.7.2. Total diagnosed prevalent cases of Glaucoma in Japan
9.7.3. Type-specific Diagnosed Prevalent Cases of Glaucoma in Japan
9.7.4. Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in Japan
9.7.5. Gender-specific Diagnosed Prevalent Cases of Glaucoma in Japan
9.7.6. Age-specific Diagnosed Prevalent Cases of Glaucoma in Japan
10. Patient Journey
11. Marketed Therapies
11.1. Key Cross Competition
11.2. OMLONTI/ EYBELIS (omidenepag isopropyl): Santen Pharmaceutical/Ube Industries
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Clinical Development
11.2.5. Clinical Trials Information
11.2.6. Safety and Efficacy
11.2.7. Product Profile
11.3. IYUZEH (latanoprost, 0.005%): Thea Pharma, Inc.
11.3.1. Product Description
11.3.2. Regulatory Milestones
11.3.3. Other Developmental Activities
11.3.4. Safety and Efficacy
11.3.5. Product Profile
11.4. GLA-ALPHA (ripasudil hydrochloride hydrate/brimonidine tartrate): Kowa Company/D. Western Therapeutics Institute
11.4.1. Product Description
11.4.2. Regulatory Milestone
11.4.3. Other Developmental Activities
11.4.4. Clinical Development
11.4.5. Safety and Efficacy
11.4.6. Product Profile
11.5. DURYSTA (bimatoprost SR): AbbVie Inc.
11.5.1. Product Description
11.5.2. Regulatory Milestones
11.5.3. Other Developmental Activities
11.5.4. Clinical Development
11.5.5. Clinical Trials Information
11.5.6. Safety and Efficacy
11.5.7. Product Profile
11.6. VYZULTA (latanoprostene bunod): Bausch and Lomb
11.6.1. Product Description
11.6.2. Regulatory Milestones
11.6.3. Other Developmental Activities
11.6.4. Clinical Development
11.6.5. Clinical Trials Information
11.6.6. Safety and Efficacy
11.6.7. Product Profile
11.7. XELPROS (latanoprost ophthalmic emulsion) 0.005%: Sun Pharma Advanced Research Company Limited
11.7.1. Product Description
11.7.2. Regulatory Milestones
11.7.3. Other Developmental Activities
11.7.4. Safety and Efficacy
11.7.5. Product Profile
11.8. SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%: Alcon
11.8.1. Product Description
11.8.2. Regulatory Milestones
11.8.3. Other Developmental Activities
11.8.4. Clinical Development
11.8.5. Clinical Trials Information
11.8.6. Safety and Efficacy
11.8.7. Product Profile
11.9. RHOPRESSA/ RHOKIINSA (netarsudil, 0.02%): Aerie Pharmaceuticals
11.9.1. Product Description
11.9.2. Regulatory Milestones
11.9.3. Other Developmental Activities
11.9.4. Clinical Development
11.9.5. Clinical Trials Information
11.9.6. Safety and Efficacy
11.9.7. Product Profile
11.10. ROCKLATAN/ ROCLANDA (netarsudil/latanoprost, 0.02%/0.005%): Aerie Pharmaceuticals
11.10.1. Product Description
11.10.2. Regulatory Milestones
11.10.3. Other Developmental Activities
11.10.4. Clinical Development
11.10.5. Clinical Trials Information
11.10.6. Safety and Efficacy
11.10.7. Product Profile
11.11. GLANATEC (ripasudil): D.Western Therapeutics Institute (DWTI)/Kowa Ltd.
11.11.1. Product Description
11.11.2. Regulatory Milestones
11.11.3. Clinical Development
11.11.4. Clinical Trials Information
11.11.5. Safety and Efficacy
11.11.6. Product Profile
11.12. TAPTIQOM/ TAPCOM (tafluprost/timolol maleate): Santen Pharmaceutical Co., Ltd.
11.12.1. Product Description
11.12.2. Regulatory Milestones
11.12.3. Other Developmental Activities
11.12.4. Clinical Development
11.12.5. Clinical Trials Information
11.12.6. Safety and Efficacy
11.12.7. Product Profile
11.13. TRAVATAN/TRAVATAN Z (travoprost, 0.004%): Novartis
11.13.1. Product Description
11.13.2. Regulatory Milestones
11.13.3. Other Developmental Activities
11.13.4. Clinical Development
11.13.5. Clinical Trials Information
11.13.6. Safety and Efficacy
11.13.7. Product Profile
11.14. LUMIGAN 0.01% (bimatoprost ophthalmic solution): Allergan
11.14.1. Product Description
11.14.2. Regulatory Milestones
11.14.3. Other Developmental Activities
11.14.4. Clinical Development
11.14.5. Clinical Trials Information
11.14.6. Safety and Efficacy
11.14.7. Product Profile
11.15. AILAMIDE (brimonidine tartrate/brinzolamide): Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd.
11.15.1. Product Description
11.15.2. Regulatory Milestones
11.15.3. Other Developmental Activities
11.15.4. Clinical Development
11.15.5. Product Profile
11.16. AIBETA (brimonidine tartrate/timolol maleate): Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd.
11.16.1. Product Description
11.16.2. Regulatory Milestones
11.16.3. Other Developmental Activities
11.16.4. Clinical Development
11.16.5. Product Profile
11.17. ZIOPTAN (tafluprost): Merck & Co
11.17.1. Product Description
11.17.2. Regulatory Milestones
11.17.3. Other Developmental Activities
11.17.4. Clinical Development
11.17.5. Clinical Trials Information
11.17.6. Safety and Efficacy
11.17.7. Product Profile
11.18. DuoTrav PQ (travoprost/timolol): Novartis/Alcon Research
11.18.1. Product Description
11.18.2. Regulatory Milestones
11.18.3. Other Developmental Activities
11.18.4. Clinical Development
11.18.5. Clinical Trials Information
11.18.6. Safety and Efficacy
11.18.7. Product Profile
12. Emerging Therapies
12.1. Key Cross Competition
12.2. NCX-470: Nicox Ophthalmics
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Clinical Trials Information
12.2.5. Safety and Efficacy
12.2.6. Product Profile
12.2.7. Analyst Views
12.3. PDP-716 (Brimonidine Tartrate Ophthalmic Suspension): Sun Pharma Advanced Research Company Limited (SPARC)/ Visiox Pharma
12.3.1. Product Description
12.3.2. Other Developmental Activities
12.3.3. Clinical Development
12.3.4. Clinical Trials Information
12.3.5. Safety and Efficacy
12.3.6. Product Profile
12.3.7. Analyst Views
12.4. TC-002 (latanoprost): TearClear
12.4.1. Product Description
12.4.2. Other Developmental Activities
12.4.3. Clinical Development
12.4.4. Clinical Trials Information
12.4.5. Safety and Efficacy
12.4.6. Product Profile
12.4.7. Analyst Views
12.5. iDose TR (Travoprost Intraocular Implant): Glaukos Corporation
12.5.1. Product Description
12.5.2. Other Developmental Activities
12.5.3. Clinical Development
12.5.4. Clinical Trials Information
12.5.5. Safety and Efficacy
12.5.6. Product Profile
12.5.7. Analyst Views
12.6. Sepetaprost/ DE-126/ ONO-9054/ STN-1012600: Santen Inc/Ono Pharmaceutical
12.6.1. Product Description
12.6.2. Other Developmental Activities
12.6.3. Clinical Development
12.6.4. Clinical Trials Information
12.6.5. Safety and Efficacy
12.6.6. Product Profile
12.6.7. Analysts’ Views
12.7. Catioprost/ DE-130A/ STN1013001: Santen Pharmaceuticals
12.7.1. Product Description
12.7.2. Other Developmental Activity
12.7.3. Clinical Development
12.7.4. Clinical Trials Information
12.7.5. Safety and Efficacy
12.7.6. Product Profile
12.7.7. Analysts’ Views
12.8. Citicoline eye drops 2%: Omikron Italia S.r.l./OPIS Spain
12.8.1. Product Description
12.8.2. Clinical Development
12.8.3. Clinical Trials Information
12.8.4. Safety and Efficacy
12.8.5. Product Profile
12.9. H-1337: D. Western Therapeutics Institute (DWTI)
12.9.1. Product Description
12.9.2. Other Developmental Activity
12.9.3. Clinical Development
12.9.4. Clinical Trials Information
12.9.5. Safety and Efficacy
12.9.6. Product Profile
12.9.7. Analysts’ Views
12.10. OTX-TIC: Ocular Therapeutix, Inc.
12.10.1. Product Description
12.10.2. Other Developmental Activities
12.10.3. Clinical Development
12.10.4. Clinical Trials Information
12.10.5. Safety and Efficacy
12.10.6. Product Profile
12.10.7. Analysts’ Views
12.11. LL-BMT1: MediPrint Ophthalmics (formerly Leo Lens Pharma)
12.11.1. Product Description
12.11.2. Other Developmental Activities
12.11.3. Clinical Development
12.11.4. Clinical Trials Information
12.11.5. Safety and Efficacy
12.11.6. Product Profile
12.11.7. Analyst Views
12.12. TRS01: Tarsier Pharma
12.12.1. Product Description
12.12.2. Other Developmental Activity
12.12.3. Clinical Development
12.12.4. Clinical Trials Information
12.12.5. Product Profile
12.12.6. Analysts’ Views
12.13. POLAT-001 (Liposomal latanoprost): Peregrine Ophthalmic
12.13.1. Product Description
12.13.2. Other Developmental Activities
12.13.3. Clinical Development
12.13.4. Clinical Trials Information
12.13.5. Product Profile
12.14. Nyxol (Phentolamine Mesylate): Ocuphire Pharma
12.14.1. Product Description
12.14.2. Other Developmental Activities
12.14.3. Clinical Development
12.14.4. Clinical Trials Information
12.14.5. Safety and Efficacy
12.14.6. Product Profile
12.15. QLS-101: Qlaris Bio, Inc.
12.15.1. Product Description
12.15.2. Other Developmental Activities
12.15.3. Clinical Development
12.15.4. Clinical Trials Information
12.15.5. Safety and Efficacy
12.15.6. Product Profile
12.16. BTQ-1902: Betaliq, Inc.
12.16.1. Product Description
12.16.2. Other Developmental Activities
12.16.3. Clinical Development
12.16.4. Clinical Trials Information
12.16.5. Product Profile
12.17. VVN539: VivaVision Biotech, Inc.
12.17.1. Product Description
12.17.2. Clinical Development
12.17.3. Clinical Trials Information
12.17.4. Product Profile
13. Glaucoma: Market Analysis
13.1. Key Findings
13.2. Key Market Forecast Assumptions
13.3. Market Outlook
13.4. Attribute Analysis
13.5. Market Size of Glaucoma in the 7MM
13.6. Total Market Size of Glaucoma by Therapies in the 7MM
13.7. Market Size of Glaucoma in the United States
13.7.1. Total Market Size of Glaucoma
13.7.2. Market size of Glaucoma by Therapies
13.8. Market Size of Glaucoma in EU4 and the UK
13.8.1. Germany
13.8.1.1. Total Market Size of Glaucoma
13.8.1.2. Market size of Glaucoma by Therapies
13.8.2. France
13.8.2.1. Total Market Size of Glaucoma
13.8.2.2. Market size of Glaucoma by Therapies
13.8.3. Italy
13.8.3.1. Total Market Size of Glaucoma
13.8.3.2. Market size of Glaucoma by Therapies
13.8.4. Spain
13.8.4.1. Total Market Size of Glaucoma
13.8.4.2. Market size of Glaucoma by Therapies
13.8.5. The UK
13.8.5.1. Total Market Size of Glaucoma
13.8.5.2. Market size of Glaucoma by Therapies
13.9. Market Size of Glaucoma in Japan
13.9.1. Total Market Size of Glaucoma
13.9.2. Market size of Glaucoma by Therapies
14. Key Opinion Leaders’ Views15. SWOT Analysis16. Unmet needs
17. Market Access and Reimbursement
17.1. The United States
17.1.1. Centre for Medicare and Medicaid Services (CMS)
17.2. In EU4 and the UK
17.2.1. Germany
17.2.2. France
17.2.3. Italy
17.2.4. Spain
17.2.5. The United Kingdom
17.3. Japan
17.3.1. MHLW
18. Appendix
18.1. Bibliography
18.2. Acronyms and Abbreviations
19. Report Methodology20. Publisher Capabilities21. Disclaimer
List of Tables
Table 1: Summary of Glaucoma Market and Epidemiology (2019-2032)
Table 2: Key Events
Table 3: Two Classes of POAG Mutations
Table 4: Genes associated with the risk of POAG
Table 5: Genes Identified in Linkage or Association With PACG
Table 6: Clinical Findings That Define Patients Seen With Angle-closure Disease
Table 7: Differential Diagnosis for Glaucoma
Table 8: The Definitions and Levels of Evidence to Rate Individual Studies
Table 9: Recommendations for Care are Formed Based on the Body of the Evidence. The Body of Evidence Quality Ratings are Defined by GRADE
Table 10: POAG Preferred Practice Pattern Guidelines
Table 11: Primary Closed-angle Glaucoma Preferred Practice Pattern Guidelines
Table 12: Time to Next Assessment for People With Suspected COAG
Table 13: Time to Next Assessment for People With COAG
Table 14: Initiating Open-angle Glaucoma Care - International Recommendations
Table 15: Medicines for Glaucoma Care International Recommendations
Table 16: Initiating Closed-angle Care - International Recommendations
Table 17: Unstable Closed-angle Glaucoma - International Recommendations
Table 18: Level of Evidence and Recommendation in Medical Treatment of PACG
Table 19: Level of Evidence and Recommendation in Treatment Laser del PACG
Table 20: Level of Evidence and Recommendation in the Surgical Treatment of PACG
Table 21: Total Prevalent Cases of Glaucoma in the 7MM (2019-2032)
Table 22: Total Diagnosed Prevalent Cases of Glaucoma in the 7MM (2019-2032)
Table 23: Total Prevalent Cases of Glaucoma in the US (2019-2032)
Table 24: Total Diagnosed Prevalent Cases of Glaucoma in the US (2019-2032)
Table 25: Type-specific Diagnosed Prevalent Cases of Glaucoma in the US (2019-2032)
Table 26: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in the US (2019-2032)
Table 27: Gender-specific Diagnosed Prevalent Cases of Glaucoma in the US (2019-2032)
Table 28: Age-specific Diagnosed Prevalent Cases of Glaucoma in the US (2019-2032)
Table 29: Total Prevalent Cases of Glaucoma in Germany (2019-2032)
Table 30: Total Prevalent Cases of Glaucoma in France (2019-2032)
Table 31: Total Prevalent Cases of Glaucoma in Italy (2019-2032)
Table 32: Total Prevalent Cases of Glaucoma in Spain (2019-2032)
Table 33: Total Prevalent Cases of Glaucoma in the UK (2019-2032)
Table 34: Total Prevalent Cases of Glaucoma in EU4 and the UK (2019-2032)
Table 35: Total Diagnosed Prevalent Cases of Glaucoma in Germany (2019-2032)
Table 36: Total Diagnosed Prevalent Cases of Glaucoma in France (2019-2032)
Table 37: Total Diagnosed Prevalent Cases of Glaucoma in Italy (2019-2032)
Table 38: Total Diagnosed Prevalent Cases of Glaucoma in Spain (2019-2032)
Table 39: Total Diagnosed Prevalent Cases of Glaucoma in the UK (2019-2032)
Table 40: Total Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK (2019-2032)
Table 41: Type-specific Diagnosed Prevalent Cases of Glaucoma in Germany (2019-2032)
Table 42: Type-specific Diagnosed Prevalent Cases of Glaucoma in France (2019-2032)
Table 43: Type-specific Diagnosed Prevalent Cases of Glaucoma in Italy (2019-2032)
Table 44: Type-specific Diagnosed Prevalent Cases of Glaucoma in Spain (2019-2032)
Table 45: Type-specific Diagnosed Prevalent Cases of Glaucoma in the UK (2019-2032)
Table 46: Type-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK (2019-2032)
Table 47: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in Germany (2019-2032)
Table 48: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in France (2019-2032)
Table 49: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in Italy (2019-2032)
Table 50: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in Spain (2019-2032)
Table 51: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in the UK (2019-2032)
Table 52: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in EU4 and the UK (2019-2032)
Table 53: Gender-specific Diagnosed Prevalent Cases of Glaucoma in Germany (2019-2032)
Table 54: Gender-specific Diagnosed Prevalent Cases of Glaucoma in France (2019-2032)
Table 55: Gender-specific Diagnosed Prevalent Cases of Glaucoma in Italy (2019-2032)
Table 56: Gender-specific Diagnosed Prevalent Cases of Glaucoma in Spain (2019-2032)
Table 57: Gender-specific Diagnosed Prevalent Cases of Glaucoma in the UK (2019-2032)
Table 58: Gender-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK (2019-2032)
Table 59: Age-specific Diagnosed Prevalent Cases of Glaucoma in Germany (2019-2032)
Table 60: Age-specific Diagnosed Prevalent Cases of Glaucoma in France (2019-2032)
Table 61: Age-specific Diagnosed Prevalent Cases of Glaucoma in Italy (2019-2032)
Table 62: Age-specific Diagnosed Prevalent Cases of Glaucoma in Spain (2019-2032)
Table 63: Age-specific Diagnosed Prevalent Cases of Glaucoma in the UK (2019-2032)
Table 64: Age-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK (2019-2032)
Table 65: Total Prevalent Cases of Glaucoma in Japan (2019-2032)
Table 66: Total Diagnosed Prevalent Cases of Glaucoma in Japan (2019-2032)
Table 67: Type-specific Diagnosed Prevalent Cases of Glaucoma in Japan (2019-2032)
Table 68: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in Japan (2019-2032)
Table 69: Gender-specific Diagnosed Prevalent Cases of Glaucoma in Japan (2019-2032)
Table 70: Age-specific Diagnosed Prevalent Cases of Glaucoma in Japan (2019-2032)
Table 71: Key cross competition- Marketed drugs
Table 72: EYBELIS (DE-117), Clinical Trial Description, 2023
Table 73: K-232, Clinical Trial Description, 2023
Table 74: DURYSTA (bimatoprost SR), Clinical Trial Description, 2023
Table 75: VYZULTA (latanoprostene bunod), Clinical Trial Description, 2023
Table 76: SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, Clinical Trial Description, 2023
Table 77: RHOPRESSA (netarsudil, 0.02%), Clinical Trial Description, 2023
Table 78: ROCKLATAN (netarsudil/latanoprost 0.02%/0.005%), Clinical Trial Description, 2023
Table 79: Glanatec, Clinical Trial Description, 2023
Table 80: TAPCOM/DE-111(tafluprost/timolol maleate) Clinical Trial Description, 2023
Table 81: TRAVATAN Z (travoprost ophthalmic solution) 0.004%, Clinical Trial Description, 2023
Table 82: LUMIGAN (bimatoprost, 0.01%), Clinical Trial Description, 2023
Table 83: ZIOPTAN (Tafluprost), Clinical Trial Description, 2023
Table 84: DuoTrav, Clinical Trial Description, 2023
Table 85: Comparison of Emerging Drugs
Table 86: NCX 470, Clinical Trial Description, 2023
Table 87: PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), Clinical Trial Description, 2023
Table 88: TC-002 (Latanoprost ophthalmic solution), Clinical Trial Description, 2023
Table 89: iDose TR (Travoprost Intraocular Implant), Clinical Trial Description, 2023
Table 90: Sepetaprost (DE-126/ STN1012600), Clinical Trial Description, 2023
Table 91: DE-130A (Catioprost), Clinical Trial Description, 2023
Table 92: Citicoline eye drops 2%, Clinical Trial Description, 2023
Table 93: H-1337, Clinical Trial Description, 2023
Table 94: OTX-TIC, Clinical Trial Description, 2023
Table 95: LL-BMT1, Clinical Trial Description, 2023
Table 96: TRS01, Clinical Trial Description, 2023
Table 97: POLAT-001, Clinical Trial Description, 2023
Table 98: Nyxol (Phentolamine Mesylate), Clinical Trial Description, 2023
Table 99: QLS-101, Clinical Trial Description, 2023
Table 100: BTQ-1902, Clinical Trial Description, 2023
Table 101: VVN539, Clinical Trial Description, 2023
Table 102: Key Market Forecast Assumptions for OMLONTI
Table 103: Key Market Forecast Assumptions for IYUZEH
Table 104: Key Market Forecast Assumptions for Rocklatan/ Roclanda
Table 105: Key Market Forecast Assumptions for Rhopressa/Rhokiinsa
Table 106: Key Market Forecast Assumptions for GLA-ALPHA
Table 107: Key Market Forecast Assumptions for Citicoline eye drops 2%
Table 108: Key Market Forecast Assumptions for NCX 470
Table 109: Key Market Forecast Assumptions for PDP-716
Table 110: Key Market Forecast Assumptions for TC-002
Table 111: Key Market Forecast Assumptions for iDose TR
Table 112: Key Market Forecast Assumptions for Sepetaprost (DE-126)
Table 113: Key Market Forecast Assumptions for DE-130A (Catioprost)
Table 114: Key Market Forecast Assumptions for H-1337
Table 115: Key Market Forecast Assumptions for OTX-TIC
Table 116: Key Market Forecast Assumptions for LL-BMT1
Table 117: Currently Prescribed Classes and Their Side-effects
Table 118: Drugs in Emerging Pipeline
Table 119: Total Market Size of Glaucoma in the 7MM, in USD million (2019-2032)
Table 120: Market Size of Glaucoma by Therapies in the 7MM, in USD million (2019-2032)
Table 121: Market Size of Glaucoma in the US, in USD million (2019-2032)
Table 122: Market Size of Glaucoma by Therapies in the US, in USD million (2019-2032)
Table 123: Market Size of Glaucoma in Germany, in USD million (2019-2032)
Table 124: Market Size of Glaucoma in France, in USD million (2019-2032)
Table 125: Market Size of Glaucoma in Italy, in USD million (2019-2032)
Table 126: Market Size of Glaucoma in Spain, in USD million (2019-2032)
Table 127: Market Size of Glaucoma in the UK, in USD million (2019-2032)
Table 128: Market Size of Glaucoma in EU4 and the UK, in USD million (2019-2032)
Table 129: Market Size of Glaucoma by Therapies in Germany, in USD million (2019-2032)
Table 130: Market Size of Glaucoma by Therapies in France, in USD million (2019-2032)
Table 131: Market Size of Glaucoma by Therapies in Italy, in USD million (2019-2032)
Table 132: Market Size of Glaucoma by Therapies in Spain, in USD million (2019-2032)
Table 133: Market Size of Glaucoma by Therapies in the UK, in USD million (2019-2032)
Table 134: Market Size of Glaucoma by Therapies in EU4 and the UK, in USD million (2019-2032)
Table 135: Market Size of Glaucoma in Japan, in USD million (2019-2032)
Table 136: Market Size of Glaucoma by Therapies in Japan, in USD million (2019-2032)
List of Figures
Figure 1: Classification of Glaucoma
Figure 2: Classification of OAG
Figure 3: Classification of OAG
Figure 4: Risk Factors Associated With POAG
Figure 5: Classification of Close-angle Glaucoma
Figure 6: Symptoms of OAG
Figure 7: Symptoms of Closed-angle Glaucoma
Figure 8: Proposed Pathways for Normal Secretion of Myocilin Into the Aqueous Humor and for Secretion Reduced by an MYOC Mutation
Figure 9: Diagnosis of Glaucoma
Figure 10: Glaucoma Assessment (Optic Nerve)
Figure 11: Evaluation of a glaucoma suspect (OAG)
Figure 12: Treatment of Glaucoma
Figure 13: Treatment Algorithm for Open-angle Glaucoma
Figure 14: Treatment of Primary Open-angle Glaucoma
Figure 15: Total Prevalent Cases of Glaucoma in the 7MM (2019-2032)
Figure 16: Total Diagnosed Prevalent Cases of Glaucoma in the 7MM (2019-2032)
Figure 17: Total Prevalent Cases of Glaucoma in the US (2019-2032)
Figure 18: Total Diagnosed Prevalent Cases of Glaucoma in the US (2019-2032)
Figure 19: Type-specific Diagnosed Prevalent Cases of Glaucoma in the US (2019-2032)
Figure 20: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in the US (2019-2032)
Figure 21: Gender-specific Diagnosed Prevalent Cases of Glaucoma in the US (2019-2032)
Figure 22: Age-specific Diagnosed Prevalent Cases of Glaucoma in the US (2019-2032)
Figure 23: Total Prevalent Cases of Glaucoma in EU4 and the UK (2019-2032)
Figure 24: Total Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK (2019-2032)
Figure 25: Type-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK (2019-2032)
Figure 26: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in EU4 and the US (2019-2032)
Figure 27: Gender-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK (2019-2032)
Figure 28: Age-specific Diagnosed Prevalent Cases of Glaucoma in EU4 and the UK (2019-2032)
Figure 29: Total Prevalent Cases of Glaucoma in Japan (2019-2032)
Figure 30: Total Diagnosed Prevalent Cases of Glaucoma in Japan (2019-2032)
Figure 31: Type-specific Diagnosed Prevalent Cases of Glaucoma in Japan (2019-2032)
Figure 32: Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma in Japan (2019-2032)
Figure 33: Gender-specific Diagnosed Prevalent Cases of Glaucoma in Japan (2019-2032)
Figure 34: Age-specific Diagnosed Prevalent Cases of Glaucoma in Japan (2019-2032)
Figure 35: Patient Journey of Glaucoma
Figure 36: Primary endpoint of DE-126
Figure 37: Primary endpoint of DE-130A
Figure 38: Secondary endpoint of DE-130A
Figure 39: Total Market Size of Glaucoma in the 7MM, in USD million (2019-2032)
Figure 40: Total Market Size of Glaucoma in the 7MM by Therapies, in USD million (2019-2032)
Figure 41: Market Size of Glaucoma in the US, in USD million (2019-2032)
Figure 42: Total Market Size of Glaucoma by Therapies in the US, in USD million (2019-2032)
Figure 43: Market Size of Glaucoma in EU4 and the UK, in USD million (2019-2032)
Figure 44: Total Market Size of Glaucoma by Therapies in EU4 and the UK, in USD million (2019-2032)
Figure 45: Market Size of Glaucoma in Japan, in USD million (2019-2032)
Figure 46: Total Market Size of Glaucoma by Therapies in Japan, in USD million (2019-2032)
Figure 47: Unmet Needs
Figure 48: Health Technology Assessment
Figure 49: Reimbursement Process in Germany
Figure 50: Reimbursement Process in France
Figure 51: Reimbursement Process in Spain
Figure 52: Reimbursement Process in the United Kingdom
Figure 53: Reimbursement Process in Japan

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Nicox Ophthalmics
  • Sun Pharma Advanced Research Company Limited (SPARC)
  • Visiox Pharma
  • TearClear
  • Glaukos Corporation
  • Santen Inc
  • Ono Pharmaceutical
  • Santen Pharmaceuticals
  • Omikron Italia S.r.l.
  • OPIS Spain
  • Ocular Therapeutix, Inc.
  • MediPrint Ophthalmics (formerly Leo Lens Pharma)
  • Tarsier Pharma
  • Peregrine Ophthalmic
  • Ocuphire Pharma
  • Qlaris Bio, Inc.
  • Betaliq, Inc.
  • VivaVision Biotech, Inc.
  • D. Western Therapeutics Institute (DWTI)